GB0313677D0 - Novel compound - Google Patents

Novel compound

Info

Publication number
GB0313677D0
GB0313677D0 GBGB0313677.7A GB0313677A GB0313677D0 GB 0313677 D0 GB0313677 D0 GB 0313677D0 GB 0313677 A GB0313677 A GB 0313677A GB 0313677 D0 GB0313677 D0 GB 0313677D0
Authority
GB
United Kingdom
Prior art keywords
novel compound
novel
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0313677.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Priority to GBGB0313677.7A priority Critical patent/GB0313677D0/en
Publication of GB0313677D0 publication Critical patent/GB0313677D0/en
Priority to PCT/GB2004/002450 priority patent/WO2004111001A1/en
Priority to ES04736421T priority patent/ES2391634T3/es
Priority to CA2528322A priority patent/CA2528322C/en
Priority to CNB2004800162994A priority patent/CN100422150C/zh
Priority to BRPI0411293A priority patent/BRPI0411293A8/pt
Priority to AU2004247468A priority patent/AU2004247468B2/en
Priority to US10/560,383 priority patent/US8022219B2/en
Priority to JP2006516390A priority patent/JP4780784B2/ja
Priority to EP04736421A priority patent/EP1641755B1/en
Priority to IL172541A priority patent/IL172541A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
GBGB0313677.7A 2003-06-13 2003-06-13 Novel compound Ceased GB0313677D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB0313677.7A GB0313677D0 (en) 2003-06-13 2003-06-13 Novel compound
EP04736421A EP1641755B1 (en) 2003-06-13 2004-06-09 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentlyoxybenzyl)piperidine as glucosylceramide synthase (gcs) inhibitor
CNB2004800162994A CN100422150C (zh) 2003-06-13 2004-06-09 用作葡糖苷酰鞘氨醇合酶(gcs)的2-(羟基甲基)-1-[(4-(戊氧基)苯基)甲基]-3,4,5-哌啶三醇
ES04736421T ES2391634T3 (es) 2003-06-13 2004-06-09 2-Hidroximetil-3,4,5-trihidroxi-1-(4-pentiloxibencil)piperidina como inhibidor de la glucosilceramida sintasa (GCS)
CA2528322A CA2528322C (en) 2003-06-13 2004-06-09 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentlyoxybenzyl) piperidine as glucosylceramide synthase (gcs)
PCT/GB2004/002450 WO2004111001A1 (en) 2003-06-13 2004-06-09 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentlyoxybenzyl) piperidine as glucosylceramide synthase (gcs)
BRPI0411293A BRPI0411293A8 (pt) 2003-06-13 2004-06-09 Composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
AU2004247468A AU2004247468B2 (en) 2003-06-13 2004-06-09 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentlyoxybenzyl) piperidine as glucosylceramide synthase (GCS)
US10/560,383 US8022219B2 (en) 2003-06-13 2004-06-09 2-hydroxymethy1-3,4,5-trihydroxy-1-(4-pentyloxybenzyl) piperidine as glucosylceramide synthase (Gcs) inhibitor
JP2006516390A JP4780784B2 (ja) 2003-06-13 2004-06-09 Ｇｃｓ阻害性ピペリジン誘導体
IL172541A IL172541A (en) 2003-06-13 2005-12-13 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentyloxybenzyl) piperidine, a method for its manufacture, pharmaceutical compositions comprising it and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0313677.7A GB0313677D0 (en) 2003-06-13 2003-06-13 Novel compound

Publications (1)

Publication Number Publication Date
GB0313677D0 true GB0313677D0 (en) 2003-07-16

Family

ID=27590018

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0313677.7A Ceased GB0313677D0 (en) 2003-06-13 2003-06-13 Novel compound

Country Status (11)

Country Link
US (1) US8022219B2 (https=)
EP (1) EP1641755B1 (https=)
JP (1) JP4780784B2 (https=)
CN (1) CN100422150C (https=)
AU (1) AU2004247468B2 (https=)
BR (1) BRPI0411293A8 (https=)
CA (1) CA2528322C (https=)
ES (1) ES2391634T3 (https=)
GB (1) GB0313677D0 (https=)
IL (1) IL172541A (https=)
WO (1) WO2004111001A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
AU2003246942B2 (en) 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
AU2003248960B2 (en) * 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0313678D0 (en) * 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
US7723378B2 (en) 2005-03-23 2010-05-25 Actelion Pharmaceuticals Ltd. Hydrogenated benzo (C) thiophene derivatives as immunomodulators
WO2013079580A1 (en) 2011-11-29 2013-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of darier disease
EA201891170A1 (ru) 2015-11-18 2018-11-30 Джензим Корпорейшн Биомаркер поликистозной болезни почек и варианты его применения
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
WO2020229968A1 (en) 2019-05-10 2020-11-19 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof
PH12022552955A1 (en) 2020-05-07 2024-02-26 Alectos Therapeutics Inc Non-lysosomal glucosylceramidase inhibitors and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE3007078A1 (de) * 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
DE3024901A1 (de) 1980-07-01 1982-01-28 Bayer Ag, 5090 Leverkusen Herbizide mittel auf basis von piperidin-derivaten
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
US5003072A (en) * 1988-11-03 1991-03-26 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
JPH02306962A (ja) 1989-05-19 1990-12-20 Meiji Seika Kaisha Ltd 新規ｎ―置換―１―デオキシノジリマイシン誘導体及びそれを含有する癌細胞転移抑制剤
JPH0324057A (ja) 1989-06-22 1991-02-01 Tosoh Corp ポリヒドロキシピペリジン類及びその製造法
KR920703056A (ko) 1989-09-07 1992-12-17 아만 히데아키 항 바이러스제
CA2086413A1 (en) 1990-06-29 1991-12-30 Yohji Ezure Piperidine derivatives
US5276120A (en) * 1991-05-30 1994-01-04 The Scripps Research Institute Process for forming omega-deuxy-azasugars
ATE318910T1 (de) 1993-05-05 2006-03-15 Roche Diagnostics Gmbh Cholesterinoxidase aus brevibacterium sterolicum
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5798366A (en) 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US5451679A (en) * 1994-03-08 1995-09-19 G. D. Searle & Co. 2-chloro and 2-bromo derivatives of 1,5-iminosugars
US6177447B1 (en) 1996-07-15 2001-01-23 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
IL132170A0 (en) * 1997-05-06 2001-03-19 Novo Nordisk As Novel heterocyclic compounds
AU8286998A (en) * 1997-07-03 1999-01-25 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Genes for niemann-pick type c disease
DK1030839T3 (da) * 1997-11-10 2004-05-03 Searle & Co Anvendelse af alkylerede iminosukkere til behandling af multidrugresistens
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
WO2000056334A1 (en) 1999-03-19 2000-09-28 The Trustees Of Boston College Use of imino sugars for anti-tumor therapy
GB9909064D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
ATE234626T1 (de) * 1999-07-26 2003-04-15 Searle & Co Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
US7256005B2 (en) * 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
AU1840101A (en) 1999-08-10 2001-03-05 Chancellor, Masters And Scholars Of The University Of Oxford, The Long chain n-alkyl compounds and oxo-derivatives thereof
AU2002246864A1 (en) 2000-12-27 2002-07-24 The Trustees Of Columbia University In The City Of New York Pim kinase-related methods
DE60308378T2 (de) * 2002-03-13 2007-09-20 Unither Pharmaceuticals, Inc. Nicht-Hormonal Verfahren zur männlichen Verhütung
AU2003246942B2 (en) 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
AU2003248960B2 (en) 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
GB0313678D0 (en) * 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0400812D0 (en) * 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds

Also Published As

Publication number Publication date
IL172541A0 (en) 2006-04-10
US20070259918A1 (en) 2007-11-08
CN100422150C (zh) 2008-10-01
AU2004247468A1 (en) 2004-12-23
BRPI0411293A8 (pt) 2017-12-26
JP4780784B2 (ja) 2011-09-28
CA2528322C (en) 2012-07-31
US8022219B2 (en) 2011-09-20
EP1641755B1 (en) 2012-08-15
CA2528322A1 (en) 2004-12-23
BRPI0411293A (pt) 2006-08-29
JP2006527252A (ja) 2006-11-30
IL172541A (en) 2011-07-31
CN1805934A (zh) 2006-07-19
ES2391634T3 (es) 2012-11-28
WO2004111001A1 (en) 2004-12-23
AU2004247468B2 (en) 2009-11-19
EP1641755A1 (en) 2006-04-05

Similar Documents

Publication Publication Date Title
GB0305918D0 (en) Novel compounds
GB0304424D0 (en) Novel compounds
GB0305927D0 (en) Compound
GB0306718D0 (en) Compound
EP1596860A4 (en) NEW CONNECTIONS
GB0313678D0 (en) Novel compounds
GB0324792D0 (en) Compound
GB0322629D0 (en) Novel compound
GB0313677D0 (en) Novel compound
GB0317841D0 (en) Compound
GB0305426D0 (en) Novel compounds
GB0317842D0 (en) Compound
GB0302431D0 (en) Novel compounds
GB0302546D0 (en) Novel compounds
GB0304809D0 (en) Novel compounds
GB0324599D0 (en) Compound
GB0327738D0 (en) Novel compound
GB0306717D0 (en) Compound
GB0328509D0 (en) Compound
GB0300714D0 (en) Compound
GB0330013D0 (en) Compound
GB0316107D0 (en) Compound
GB0318345D0 (en) Compound
GB0318347D0 (en) Compound
GB0315885D0 (en) Compound

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)